

Upcoming Commercial Pharmacy Benefit Change

Neighborhood News – January 2025

As of **January 1, 2025**, Neighborhood Health Plan of Rhode Island's (Neighborhood) Commercial Pharmacy Benefit will prefer biosimilar Humira products and remove Humira from the formulary. Neighborhood will **exclusively prefer the following adalimumab biosimilars:**

- Hyrimoz
- Adalimumab-adaz

Due to this change, Commercial members currently utilizing Humira will need a new prescription for one of the preferred biosimilar products listed above.

Please note members with authorizations currently active for Humira had authorizations placed for Hyrimoz and adalimumab-adaz so that providers may begin prescribing the biosimilar products immediately.